DYN Stock Overview
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dyne Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.46 |
| 52 Week High | US$30.27 |
| 52 Week Low | US$6.40 |
| Beta | 0.95 |
| 1 Month Change | -9.84% |
| 3 Month Change | 50.12% |
| 1 Year Change | 139.29% |
| 3 Year Change | 36.00% |
| 5 Year Change | n/a |
| Change since IPO | 6.53% |
Recent News & Updates
Recent updates
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 12Dyne Therapeutics EPS beats by $0.10
May 06Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?
Jan 27Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial
Jan 11Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial
Jan 08Shareholder Returns
| DYN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | -2.5% | -3.2% |
| 1Y | 139.3% | -3.7% | 19.3% |
Return vs Industry: DYN exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: DYN exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| DYN volatility | |
|---|---|
| DYN Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DYN's share price has been volatile over the past 3 months.
Volatility Over Time: DYN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 141 | John Cox | www.dyne-tx.com |
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc. Fundamentals Summary
| DYN fundamental statistics | |
|---|---|
| Market cap | US$2.14b |
| Earnings (TTM) | -US$235.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.3x
P/E RatioIs DYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$235.94m |
| Earnings | -US$235.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DYN perform over the long term?
See historical performance and comparison